In contrast, 71% of nonresponders had an increased resistance to immunotherapy (Fig. 4h) and an increased frequency of proliferating (Ki-67+) tumor cells following treatment (Fig. 4i), consistent with the development of progressive disease in a subset of nonresponders following PD-1 blockade13,26,56. Here, PDCD1 is linked to neoplasm.